AI Article Synopsis
- - The global prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is increasing, but effective treatments are still scarce.
- - Research is focusing on the connection between the gut microbiome and MASLD, with the potential for gut-targeted therapies to help manage or prevent the disease.
- - This review will explore how the gut microbiome's structure and function relate to MASLD, evaluate gut microbiome signatures for diagnosing disease severity, and look into both current and potential therapies targeting the interactions between the gut microbiome and liver.
Article Abstract
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-previously described as nonalcoholic fatty liver disease-continues to rise globally. Despite this, therapeutic measures for MASLD remain limited. Recently, there has been a growing interest in the gut microbiome's role in the pathogenesis of MASLD. Understanding this relationship may allow for the administration of therapeutics that target the gut microbiome and/or its metabolic function to alleviate MASLD development or progression. This review will discuss the interplay between the gut microbiome's structure and function in relation to the development of MASLD, assess the diagnostic yield of gut microbiome-based signatures as a noninvasive tool to identify MASLD severity, and examine current and emerging therapies targeting the gut microbiome-liver axis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2438-4383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!